Startup Atavistik adds $40 million to clinical trial to treat unapproved rare bleeding disorder

The Series B extension brings Atavistik Bio's Series B funding to $160 million. The startup's lead program is being developed to treat hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.

The post Startup Atavistik Raises $40M for Clinical Trial to Treat Unapproved Rare Bleeding Disorder appeared first on MedCity News.